Patents Examined by Scott Long
  • Patent number: 10772914
    Abstract: Methods for generating/expanding populations of immune cells comprising immune cells specific for an Epstein Barr Virus (EBV) lytic antigen are disclosed, the methods comprising stimulating immune cells specific for an EBV lytic antigen by contacting peripheral blood mononuclear cells (PBMCs) with: (i) one or more peptides corresponding to all or part of one or more EBV lytic antigens; or (ii) antigen presenting cells (APCs) presenting one or more peptides corresponding to all or part of one or more EBV lytic antigens. Also disclosed are populations of immune cells comprising immune cells specific for an EBV lytic antigen expanded according to such methods, and uses thereof.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: September 15, 2020
    Assignee: Baylor College of Medicine
    Inventors: Cliona M. Rooney, Sandhya Sharma
  • Patent number: 10766852
    Abstract: Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent transfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: September 8, 2020
    Assignee: Translate Bio, Inc.
    Inventors: Frank DeRosa, Braydon Charles Guild, Michael Heartlein
  • Patent number: 10765706
    Abstract: Blood brain barrier (BBB) permeabilizers, such as mannitol, can facilitate the entry of stem cells from the periphery to the stroke brain. It is unknown whether BBB permeation in the chronic stage of the disease still facilitates the entry of stem cells from the periphery to the injured brain. Evidence herein shows BBB permeation in the chronic stage of stroke assisted in the entry of stem cells from the periphery to the stroke brain. Stroke models treated with human umbilical cord stem cells (hUCBC) only (2 million viable cells), mannitol or a combination. Results revealed that hUCBC alone or combined with mannitol displayed significant behavioral and histological deficits compared to control animals, with the HUCBC-mannitol combined treatment showing improvements over hUCBC only treatments in brain cell survival in the peri-infarct area. BBB permeation in chronic stroke also lowers the effective stem cell dose necessary to improve functional outcomes.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: September 8, 2020
    Assignee: University of South Florida
    Inventors: Cesario Venturina Borlongan, Paul R. Sanberg
  • Patent number: 10765739
    Abstract: The present invention relates to novel methods and compositions for increasing AMPK activity and glucose uptake comprising administering a macrophage migration inhibitory factor (MIF) pathway agonist in a subject in need thereof. The invention also relates to methods for selecting a subject for treatment with an agonist of MIF, identifying a subject at risk for developing a condition in which increased AMPK activity is desirable, and for predicting whether a subject is susceptible to a condition in which increased AMPK activity is desirable.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: September 8, 2020
    Assignee: Yale University
    Inventors: Richard Bucala, Lawrence H. Young
  • Patent number: 10758575
    Abstract: Provided herein are novel methods and composition utilizing adipose tissue-derived stromal stem cells for treating fistulae.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: September 1, 2020
    Assignees: TiGenix, S.A.U., UNIVERSIDAD AUTÓNOMA DE MADRID
    Inventors: María Gema Fernández Miguel, Manuel Ángel González De La Peña, Rosa Ana García Castro, Mariano García Arranz, Damián García Olmo
  • Patent number: 10758572
    Abstract: The present invention relates to substantially homogenous populations of human retinal progenitor cells having the following positive surface markers: SSEA4, CD73, PTK7 and PSA-NCAM. The invention also relates to method for preparing such substantially homogeneous cell populations from human tissue using cell sorting techniques.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: September 1, 2020
    Assignee: The Schepens Eye Research Institute
    Inventors: Michael J. Young, Petr Y. Baranov
  • Patent number: 10760058
    Abstract: A biological composition has a mixture of mechanically selected allogeneic biologic material derived from bone marrow. The mixture has non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components. The mixture including non-whole cell fractions including one or more of exosomes, transcriptosomes, proteasomes, membrane rafts, lipid rafts. The mixture is compatible with biologic function.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: September 1, 2020
    Assignee: Vivex Biologics Group, Inc.
    Inventors: Timothy Ganey, Wendy W. Weston, Miguel Quevedo, Stuart Oglesby, Gaetan Jean-Robert Delcroix, Paul C. Schiller, Gianluca D'Ippolito
  • Patent number: 10760050
    Abstract: The present invention provides a method for producing a retinal pigment epithelial cell, including (1) a first step of subjecting pluripotent stem cells to floating culture in a serum-free medium to form an aggregate of pluripotent stem cells, (2) a second step of subjecting the aggregate formed in step (1) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway and containing a substance acting on the BMP signal transduction pathway, thereby obtaining an aggregate containing retinal progenitor cells, and (3) a third step of subjecting the aggregate formed in step (2) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway and a substance acting on the BMP signal transduction pathway and containing a substance acting on the Wnt signal pathway, thereby obtaining an aggregate containing retinal pigment epithel
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: September 1, 2020
    Assignees: SUMITOMO CHEMICAL COMPANY, LIMITED, RIKEN
    Inventors: Tokushige Nakano, Yoshiki Sasai, Chikafumi Ozone
  • Patent number: 10752671
    Abstract: A method of making hydrolyzed marine Type II collagen includes the mixing of marine cartilage, water, an enzyme and a protease enzyme for an extended period of time. Once mixed, the mixture is heated for a period of time at 150° F. Once heated, the enzymes are deactivated, the bone sediment separated, and the fat removed. Next, maltodextrin is added to the mixture and finally the mixture is spray dried to form a collagen powder.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: August 25, 2020
    Inventor: Robert den Hoed
  • Patent number: 10752924
    Abstract: Methods for the recovery of lipids, sugars, and proteins from microbial biomass by enzymatic digestion are disclosed. The methods involve treating microalgae with a fungal acid protease, or with a mixture of at least one protease and at least one amylase.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: August 25, 2020
    Assignee: The University of Toledo
    Inventors: Agasteswar K. Vadlamani, Patricia Relue, Sridhar Viamajala, Heng Shao, Sasidhar Varanasi
  • Patent number: 10752880
    Abstract: A three-dimensional cell culture method on the basis of a biodegradable synthetic hydrogel is provided. The method may include culturing cells in a cell culture dish in a non-contact manner using a porous membrane and a biodegradable synthetic hydrogel in the culture of stem cells and primary cells.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: August 25, 2020
    Assignee: CEFO CO., LTD
    Inventors: Hyun Sook Park, Sun Ray Lee, Ji Won Yang, Seol Chu, Jang Mi Park, Hyun Jung Mo
  • Patent number: 10751276
    Abstract: The present invention relates to a composition comprising ex-vivo expanded adipose tissue derived stem cell (ASC) or ex-vivo expanded adipose tissue-derived stem cells (ASC) mixed with harvested fat tissue at a ratio of 5.0×104-2.0×108ASCs/mL fat; for example 1.0×105-2.0×107 and the use of ex-vivo expanded adipose tissue-derived stem cells or ex-vivo expanded adipose tissue-derived stem cell enriched fat grafts as an agent for cosmetic breast filling/augmentation or for facial filling/reju-venation.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: August 25, 2020
    Assignee: STEMFORM APS
    Inventor: Stig-Frederik Trojahn Kølle
  • Patent number: 10744207
    Abstract: The disclosure provides complexes comprising targeting units, methods for their production, and methods for their use. In some embodiments, complexes comprise therapeutic agents complexed with targeting units. In some embodiments, complexes comprise cells complexed with targeting units. In view of the foregoing, there is a need for improved modalities for targeting of therapeutics, in the area of immunotherapy and others. The present disclosure addresses these needs, and provides additional advantages as well.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: August 18, 2020
    Assignee: ACEPODIA, INC.
    Inventors: Amy A. Twite, Ching-Wen Hsiao, Sonny Hsiao, Cheng Liu, Hong Liu
  • Patent number: 10744172
    Abstract: A tropism modified cancer terminator virus (Ad.5/3-CTV; Ad.5/3-CTV-M7) has been found to have infectivity that is Coxsackie Adenoviral Receptor (CAR) independent. The Ad.5/3-CTV (Ad.5/3-CTV-M7) may be used alone or in combination with other therapeutic agents such as agents that augment reactive oxygen (ROS) production, HDAC inhibitors, MCL-1 inhibitors and Bcl-2 inhibitors to treat a variety of cancers particularly including malignant glioma (GBM), renal cancer, prostate cancer, and colorectal cancer.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: August 18, 2020
    Assignee: Virginia Commonwealth University
    Inventors: Paul Fisher, Devanand Sarkar, Paul Dent
  • Patent number: 10745677
    Abstract: Provided herein are systems, compositions, and methods of introducing protective and/or loss-of-function variants of CCR5 and CCR2. Variants may be introduced using a CRISPR/Cas9-based nucleobase editor or other guide nucleotide sequence-programmable DNA binding protein domain-based fusion protein described herein. Further provided herein are compositions and methods of preventing and treating conditions related to HIV infection and progression as well as to AIDS.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: August 18, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Juan Pablo Maianti, David R. Liu
  • Patent number: 10738290
    Abstract: The present invention provides RNA-guided gene editing systems and methods of use thereof.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: August 11, 2020
    Assignee: NOVARTIS AG
    Inventors: Andreas Loew, Anette Huebner
  • Patent number: 10738305
    Abstract: The present application provides materials and methods for treating hemoglobinopathies. More specifically, the application provides methods for producing progenitor cells that are genetically modified via genome editing to increase the production of fetal hemoglobin (HbF), as well as modified progenitor cells (including, for example, CD34+ human hematopoietic stem cells) producing increased levels of HbF, and methods of using such cells for treating hemoglobinopathies such as sickle cell anemia and ?-thalassemia.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: August 11, 2020
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventor: Matthew Hebden Porteus
  • Patent number: 10738099
    Abstract: The present invention relates to compositions and methods for treating of a HIV infected mammal using a CD4 membrane-bound chimeric receptor or a HIV specific scFvs CARs. One aspect includes a modified T cell and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with HIV infection.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: August 11, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James L. Riley, Rachel Leibman, Aimee S. Payne, Christoph T. Ellebrecht, Michael C. Milone
  • Patent number: 10738276
    Abstract: The present disclosure provides methods, and related kits, for directing cell attachment and spreading on a substrate and inducing isotropic spreading of cells; provides methods, and related kits, for cell sorting; and further provides methods, and related kits, for guided induction of stem cell differentiation.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: August 11, 2020
    Inventor: Shengyuan Yang
  • Patent number: 10736922
    Abstract: Disclosed are isolated human bone marrow mesenchymal stem cells having high telomerase activity (tBMMSCs). Also disclosed are isolated human CD34+ bone marrow mesenchymal stem cells. Also disclosed are bone marrow mesenchymal stem cells treated with a telomerase induction agent.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: August 11, 2020
    Assignee: University of Southern California
    Inventors: Songtao Shi, Kentaro Akiyama, Chider Chen